Research teams link response to Iressa to mutations in EGF receptor.
SPOREs hammer out research agenda, seek $50,000 from NCI for further tissue analysis.
Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.
NCI blocked groups from phase III Iressa studies.
Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.
Robert Hall appointed government relations director for National Coalition for Cancer Survivorship.
Funding opportunities listed.
April issue of Business & Regulatory Report included (8 additional pages).
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Trump 2016: A look back at the 45th president’s impact on oncology
- When cigarette filters were made of asbestos
- Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began
